How COVID-19 Has Changed the Management of Glomerular Diseases

Clin J Am Soc Nephrol. 2020 Jun 8;15(6):876-879. doi: 10.2215/CJN.04530420. Epub 2020 Apr 24.
No abstract available

Keywords: COVID-19; glomerular disease; immunosuppression; kidney diseases; severe acute respiratory syndrome coronavirus 2.

MeSH terms

  • Betacoronavirus / immunology*
  • Betacoronavirus / pathogenicity
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / virology
  • Host-Pathogen Interactions
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / adverse effects
  • Nephrosis, Lipoid / diagnosis
  • Nephrosis, Lipoid / drug therapy*
  • Nephrosis, Lipoid / immunology
  • Pandemics
  • Patient Safety
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / virology
  • Predictive Value of Tests
  • Reagent Strips
  • Recurrence
  • Risk Assessment
  • Risk Factors
  • Rituximab / administration & dosage*
  • Rituximab / adverse effects
  • SARS-CoV-2
  • Urinalysis / instrumentation

Substances

  • Immunosuppressive Agents
  • Reagent Strips
  • Rituximab